• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update

    8/30/24 4:21:06 PM ET
    $WENA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WENA alert in real time by email
    false 0001907223 0001907223 2024-08-25 2024-08-25 0001907223 us-gaap:CommonStockMember 2024-08-25 2024-08-25 0001907223 WENA:WarrantsMember 2024-08-25 2024-08-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): August 25, 2024

     

    ANEW Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-41340   86-2727441
    (Commission File Number)  

    (IRS Employer

    Identification No.)

     

    13576 Walnut Street, Suite A
    Omaha, NE 68144

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code (833) 931-6330

     

    Redwoods Acquisition Corp.

    1115 Broadway, 12th Floor

    New York, NY 10010

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Common Stock   WENA   The Nasdaq Stock Market LLC
    Warrants   WENAW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On August 25, 2024, Edward Cong Wang resigned as a member of the Company’s Board of Directors. Mr. Wang had served as a Director and Chief Financial Officer of the Company prior to the Company’s business combination and had agreed to remain as nominee of the Company’s original sponsor.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: August 30, 2024 ANEW MEDICAL, INC.
         
      By: /s/ Joseph Sinkule
      Name:  Joseph Sinkule
      Title: Chief Executive Officer

     

     

     

    Get the next $WENA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WENA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WENA
    SEC Filings

    See more
    • SEC Form EFFECT filed by ANEW MEDICAL INC.

      EFFECT - ANEW Medical, Inc. (0001907223) (Filer)

      9/19/24 12:15:16 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-1 filed by ANEW MEDICAL INC.

      S-1 - ANEW Medical, Inc. (0001907223) (Filer)

      9/5/24 12:31:49 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update

      8-K - ANEW Medical, Inc. (0001907223) (Filer)

      8/30/24 4:21:06 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Chardan Capital Markets Llc sold $725,162 worth of shares (342,136 units at $2.12) (SEC Form 4)

      4 - ANEW Medical, Inc. (0001907223) (Issuer)

      7/2/24 6:34:54 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Chardan Capital Markets Llc claimed ownership of 1,626,500 shares (SEC Form 3)

      3 - ANEW Medical, Inc. (0001907223) (Issuer)

      7/1/24 6:14:59 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

      NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's commitment to strategically direct its core investments of time and financial resources toward the multibillion-dollar market opportunities for the company's patented Klotho gene technology assets in the neurosciences sector. Through its exclusive worldwide license, the company's patent protected secr

      9/17/24 6:30:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy

      NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as "the anti-aging gene." It is named after the

      9/4/24 7:46:07 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

      NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW's balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in long-term debt not only clears ANEW's balance sheet but also significantly increases stockholder equity, positioning the company for future growth and investment opportunities. It also eliminates $600,000 in annual interest payments owed by the company. The avera

      8/26/24 5:00:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Leadership Updates

    Live Leadership Updates

    See more
    • ANEW MEDICAL, INC. Appoints New CFO

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. "Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team," commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. "Jeff has over 20 years of experience in managing financial ope

      8/19/24 5:00:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Financials

    Live finance-specific insights

    See more
    • ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ("TTS")

      NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th

      8/21/24 5:00:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ANEW MEDICAL INC.

      SC 13G - ANEW Medical, Inc. (0001907223) (Subject)

      6/27/24 5:36:14 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care